Autobahn Labs, a virtual incubator partnering with top academic and research institutions to catalyze early-stage drug discovery and development, has partnered with the University of California San Diego (UCSD) to bring novel therapeutics to market, building new seed-stage companies out of early-stage research projects. Through this partnership, Autobahn Labs grants UCSD access to Evotec International, the worldwide drug discovery and development platform, as well as basic research and preclinical work with cell lines, primary human cells, iPSCs and animal models. Autobahn Labs and UCSD look forward to a mutually beneficial relationship through which they can pool resources, funding and their robust networks of partners and investors to assist more teams and startups than ever before.

The WilmerHale team representing Autobahn Labs includes Jason Kropp, Jenna Ventorino and Ryan Crane. The team previously advised the company in a similar collaboration with UC San Francisco in December 2020.

For more information, read the UCSD interview with Autobahn’s leadership.